US Urinary Tract Infection Therapeutics outlook to 2028
Driven by rising cases of diabetes and kidney stones, rising UTI-related complications, and technological advancements

About the Report

About the Report

Market Overview:

The United States Urinary Tract Infection Therapeutics Market deals in the development of drugs and medicines for the treatment of Urinary Tract infections. UTI is a huge problem in the US. US typically see more than 8 million cases of UTIs every year.

According to Ken Research, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~2% between 2022-2028 owing to rise in cases of UTIs, technological advancements, rise in UTI-related complications and rise in cases of Diabetes and Kidney stones.

US Urinary Tract Infection Therapeutics Market

The United States Urinary Tract Infection (UTI) Therapeutics market is being driven by a number of factors such as rising cases of UTIs, complications arising due to UTIs, technological advancements and rising cases of diabetes and kidney stones. Over the years in the US, the cases of UTIs have been constantly increasing as it is one of the most common infections. More than 8 million people in the US are having problems related to UTIs. The UTI s has also been linked to causing many complications such as sepsis, kidney infection, bladder dysfunction etc. Moreover, the rising prevalence of diabetes and kidney stones also increase the risk of getting an UTI. There also have been many technological advancements such as mass spectrometry, urine NAAT test, PCR, and robotic surgery which have accelerated the market and made the work of doctors and scientists easier. All these factors contribute to the growth of US UTI Therapeutics market.

US Urinary Tract Infection Therapeutics Industry

Key trends by Market Segment:

By type of medicine: Quinolones have dominated the US UTI Therapeutics market in 2022 followed by cephalosporin. This is primarily due to the fact that these medicines are a natural alternative to trimethoprim sulfamethoxazole.

These medicines are a class of antibiotics that are typically the best option for treating many diseases caused by various bacteria. These medicines can even also work against such bacteria which are very hard to treat otherwise.

The reason why these antibiotics are dominant when it comes to treating Urinary Tract Infections is that these antibiotics are considered very safe, have high efficacy and high tolerability.

The use of these antibiotics is not limited to Urinary Tract Infections. Apart from UTIs, these antibiotics are also used to treat other health conditions like TB, kidney infection, skin infection, bronchitis, bladder infection, prostatitis, etc. Moreover, they are also used in poultry and animal husbandry.

US Urinary Tract Infection Therapeutics Market Overview

By indication: In 2022, Complicated Urinary Tract Infections dominated the UTI Therapeutics Market followed by Uncomplicated Urinary Tract Infections. A Urinary Tract Infection is said to be complicated when the patients has some already existing health condition or risk factors.

A UTI also becomes a complicated UTI if the infection persists despite taking the treatment. Moreover, an infection will also be called a complicated UTI if it involves kidney stones, catheters, urinary obstruction, fever, sepsis, etc.

United States see at least 600,000 cases of complicated UTIs every year , which makes this segment dominant in the US UTI Therapeutics Market. Such infections are also very hard to treat because most of the patients pose with an increased risk of antibiotic or treatment failure.

Generally, a person is at high risk of a complicated UTI if they are very old or young child, have a kidney disease, recently had a kidney transplant, have diabetes, cancer, are pregnant, had recently used a catheter, or have a weekend immune system.

US Urinary Tract Infection Therapeutics Sector Size

By Geography: In 2022, the western part of the United States was the dominant segment in the United States Urinary Tract Infection Therapeutics Market. The western US is composed of Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming.

The reason behind this region being the dominant segment in US UTI Therapeutics Market is primarily due to the fact that this region has the availability of reputed hospitals which also provide treatment of UTIs. Moreover, there are also many healthcare and pharmaceutical companies established in this region.

  • Some of the best hospitals located in this region of US are Mayo Clinic, Oasis Hospital, Mammoth Hospital, Grand Junction medical center, Park city hospital, Artesia General Hospital, Northwest Specialty Hospital, etc.
  • Moreover, this region of the United States also sees the highest export and import activity as compared to other regions of the country. This is one another reason behind this region being the dominant segment in the US UTI Therapeutics market as the import and export greatly help in accelerating the market.
  • Along with many reputed hospitals located in this region, there also happen to be about 10k healthcare and pharmaceutical companies situated in this region which are a key factor in the growth of US UTI Therapeutics market.

US Urinary Tract Infection Therapeutics Market Revenue

Competitive Landscape:    

There are many well-established players in the US UTI Therapeutics market such as Bristol Myers Squibb, Johnson & Johnson, Pfizer, Merck & Co., AbbVie, etc. These companies have a good amount of market share and typically have high dominance in the US UTI Therapeutics market.

However, there are also many budding players in this industry such as Dendreon, Zydus Pharmaceuticals, Agenus Inc., MacroGenics, Altimmune, etc. These companies do not have high market share, considering the fact that they are still in their growing phases.

It is evident that the United States Urinary Tract Infection Therapeutics Market has many well-established players but also leading and budding players who would continue to contribute towards the growth and expansion of this market in the US.

US Urinary Tract Infection Therapeutics Market Size

Recent Developments:

  • In July 2019, Pfizer acquired Array BioPharma which had two FDA approved drugs for the treatment of Urinary Tract Infection, i.e., BRAFTOVI, and MEKTOVI.
  • In December 2019, Johnson and Johnson completed the acquisition of TARIS Biomedical LLC which has a leading product, TAR-200 which makes sure the release of medicine into the bladder.
  • In October 2020, Bayer Ag successfully completed the acquisition of Asklepios BioPharmaceutical. Their portfolio primarily includes clinical and pre-clinical investigational candidates mainly for the treatment of metabolic, cardiovascular and neuromuscular diseases.
  • In October, 2021, Spero Therapeutics sought FDA’s approval for their Tebipenem HBr tablets as a treatment for Urinary Tract Infections.
  • In December 2022, FDA approved BRIUMVITM, and UNYVERO drug for the treatment of Urinary Tract Infection.

 

Future Outlook:

  • The US UTI Therapeutics Market is anticipated to grow at a CAGR of 2% between the time periods 2022-2028 reaching ~ USD 2Bn. industry by 2028.
  • This market will be driven by rise in UTI cases, rise in UTI-related complications, rising cases of diabetes and kidney stones along with technological advancements in the UTI therapeutics market.
  • UTI cases have been constantly rising in the country and they are expected to rise in the upcoming years. This would further accelerate the US UTI Therapeutics market.
  • Despite UTI being a common infection, it still happens to result in many complications. The rising complications are also known for driving the US UTI Therapeutics Market.
  • The prevalence of Diabetes and Kidney stones pose a risk for the development of UTIs, which will help in the growth and expansion of the US UTI Therapeutics market.

 

Scope Of The Report

Scope of the Report

US UTI Therapeutics Market Segmentation

By Type of Medicine

·       Quinolones

·       Cephalosporin

·       Penicillin and combinations

·       Others

By Indication

·       Complicated UTIs

·       Uncomplicated UTIs

·       Recurrent UTIs

·       Others

By Geography

·       North

·       East

·       West

·       South

·       Central

Report scope can be customized per your requirements. Click here.

Products

Products

Key target audience

  • Therapeutics companies
  • Potential market entrants
  • Government bodies and institutions
  • Healthcare research institutes
  • Hospitals
  • Patients
  • Investors
  • Venture Capitalists
  • Medical educational institutes

 

Time Period Captured in the Report:

  • Historical period: 2017-2022
  • Base year: 2022
  • Forecast period: 2022-2028


Companies

Companies covered in the Report:

  • Pfizer
  • Bristol Myers Squibb
  • Johnson & Johnson
  • AbbVie
  • Merck & Co.
  • Dendreon
  • Zydus Pharamceuticals

Table of Contents

Table of Contents

1. Executive Summary

2. Urinary Tract Infection Therapeutics Market Overview

2.1 Taxonomy of the Market

2.2 Industry Value Chain

2.3 Ecosystem

2.4 Government Regulations/Initiatives for the Market 

2.5 Growth Drivers of the Urinary Tract Infection Therapeutics Market

2.6 Issues and Challenges of the Urinary Tract Infection Therapeutics Market

2.7 Impact of COVID-19 on the Urinary Tract Infection Therapeutics Market

2.8 SWOT Analysis

3. Urinary Tract Infection Therapeutics Market Size, 2017 – 2022

4. Urinary Tract Infection Therapeutics Market Segmentation

4.1 By Type of medicine, 2017 - 2022

4.2 By Indication, End User, 2017 - 2022

4.3 By Regional Split (North/East/West/South/Central), 2017 - 2022

5. Competitive Landscape

5.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements

5.2 Strategies Adopted by Leading Players

5.3 Company Profiles 

5.3.1 Pfizer

5.3.2 Merck & Co. 

5.3.3 Johnson & Johnson

5.3.4 Bristol Myers Squibb

5.3.5 AbbVie

5.3.6 Dendreon

5.3.7 Zydus Pharmaceuticals

6. Urinary Tract Infection Future Market Size, 2022 – 2028

7. Urinary Tract Infection Future Market Segmentation

7.1 By Type of medicine, 2022 - 2028

7.2 By Indication, 2022 - 2028

7.3 By Regional Split (North/East/West/South/Central), 2022 – 2028

8. Analyst Recommendations

9. Research Methodology

10. Disclaimer 

11. Contact Us

You can also purchase parts of this report. Do you want to check out a section wise price list?
Get Price Break-up

Research Methodology

Research Methodology

Step 1: Identifying Key Variables: Ecosystem creation for all the major entities and referring to multiple secondary and proprietary databases to perform desk research around market to collate industry level information.

Step 2: Market building: Collating statistics on UTI Therapeutics over the years, penetration of UTI Therapeutics. We will also review US UTI Therapeutics Companies’ statistics to understand annual growth and outstanding amount which can ensure accuracy behind the data point shared.

Step 3: Validating and Finalizing: Building market hypothesis and conducting CATIs with industry exerts belonging to different companies to validate statistics and seek operational and financial information from company representatives.

Step 4: Research output: Our team will approach multiple UTI Therapeutics providing channels and understand nature of product segments and sales, consumer preference and other parameters, which will support us validate statistics derived through bottom to top approach from US UTI Therapeutics providers.

US Urinary Tract Infection Therapeutics Market

US Urinary Tract Infection Therapeutics Market Forecast

For any queries related to research methodology, click here to schedule a call with our analysts

Frequently Asked Questions

Frequently Asked Questions

How big is US urinary tract infection therapeutics market?

The Us urinary tract infection therapeutics market reached 4 billion USD in 2022 and is expected to reach 6 billion USD with a CAGR of 2% during the forecast period 2022-2028.

what are the key driving factors of US UTI therapeutics market?

Rising cases of diabetics and kidney stones, rising UTI cases and complications are key driving factors of US UTI market.

Which are the major companies of US UTI market?

Merck & Co., Johnson & Johnson, Bristol Myers Squibb, AbbVie, and Pfizer are major companies in US UTI market.

Which type of medicine is majorly use in US UTI market?

Quinolones have dominated the US UTI market. It is primarily used due to the fact that thses medicines are natural alternative to trimethoprim sulfamethoxazole.

Which region of US dominates the US UTI market?

The Western region of US dominates the US UTI market.


Pre-book this report and get huge discount

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022


Trusted By 2500+ Brands